Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of 400 mg moxifloxacin tablets in healthy Thai subjects under fasting conditions
TCTR20200309001Phase 1Not yet recruiting
- Sponsor
- T.O. Chemicals
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of moxifloxacin in bacterial disease (2 arms), sponsored by T.O. Chemicals. Primary endpoint: Plasma moxifloxacin pharmacokinetics. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
moxifloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on TCTR20200309001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200309001.